Evidence map›Paper›PMID 37253003›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2023

Succinyl-CoA ligase ADP-forming subunit beta promotes stress granule assembly to regulate redox and drive cancer metastasis.

Austin C Boese, JiHoon Kang, Jung Seok Hwang, Jaehyun Kim, Kiyoung Eun, Courteney M Malin, Kelly R Magliocca, Chaoyun Pan, Lingtao Jin, Sumin Kang

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Targeting catalase in cancer.Redox biology · 2024
    Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Austin C BoeseDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory, Emory University School of Medicine, Atlanta, GA 30322.ORCID 0000-0002-2261-3436
JiHoon KangDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory, Emory University School of Medicine, Atlanta, GA 30322.
Jung Seok HwangDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory, Emory University School of Medicine, Atlanta, GA 30322.
Jaehyun KimDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory, Emory University School of Medicine, Atlanta, GA 30322.
Kiyoung EunDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory, Emory University School of Medicine, Atlanta, GA 30322.
Courteney M MalinDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory, Emory University School of Medicine, Atlanta, GA 30322.ORCID 0000-0002-8254-5324
Kelly R MaglioccaDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322.
Chaoyun PanDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory, Emory University School of Medicine, Atlanta, GA 30322.
Lingtao JinDepartment of Molecular Medicine, University of Texas Health San Antonio, San Antonio, TX 78229.
Sumin KangDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory, Emory University School of Medicine, Atlanta, GA 30322.
Emory University · USThe University of Texas Health Science Center at San Antonio · US

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Ragini Reiney Kudchadkar · 2009 to 2026
$47.5M
Project 3: Inhibiting FAK to enhance immune checkpoint inhibitor therapy in LKB1-mutant lung adenocarcinomaP01CA257906 · NCI · EMORY UNIVERSITY · PI Gabriel Larkin Sica · 2022 to 2026
$10.7M
Transcription-dependent and -independent signaling of RSK2 in cancer metastasisR01CA175316 · NCI · EMORY UNIVERSITY · PI KANG, SUMIN · 2014 to 2023
$3.5M
The role of NFIB-MAST1 signaling in mediating adaptive cisplatin resistance in SCLCR37CA249305 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lingtao Jin · 2020 to 2026
$2.9M
The role of platinum-regulated lipid metabolism in tau-related dementiaR01CA269782 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lingtao Jin · 2022 to 2026
$2.2M
Decoding and targeting saccharopine pathway in cancer metastasisR01CA266613 · NCI · EMORY UNIVERSITY · PI Sumin Kang · 2022 to 2026
$2.1M
Role of MAST1 kinase in cisplatin resistant cancersR01CA207768 · NCI · EMORY UNIVERSITY · PI KANG, SUMIN · 2017 to 2021
$1.8M
Dissecting pemetrexed resistance in non-small cell lung carcinomaR21CA277103 · NCI · EMORY UNIVERSITY · PI KANG, SUMIN · 2023 to 2024
$391k
Metabolic reprogramming and tumor progression in LKB1 deficient NSCLCF99CA264407 · NCI · EMORY UNIVERSITY · PI BOESE, AUSTIN C · 2021 to 2022
$94k
NCI NIH HHS F99 CA264407NCI NIH HHS P01 CA257906NCI NIH HHS P30 CA138292NCI NIH HHS R01 CA175316NCI NIH HHS R01 CA207768NCI NIH HHS R01 CA266613NCI NIH HHS R01 CA269782NCI NIH HHS R21 CA277103NCI NIH HHS R37 CA249305
6 · The paper itself

Abstract

Although recent studies demonstrate active mitochondrial metabolism in cancers, the precise mechanisms through which mitochondrial factors contribute to cancer metastasis remain elusive. Through a customized mitochondrion RNAi screen, we identified succinyl-CoA ligase ADP-forming subunit beta (SUCLA2) as a critical anoikis resistance and metastasis driver in human cancers. Mechanistically, SUCLA2, but not the alpha subunit of its enzyme complex, relocates from mitochondria to the cytosol upon cell detachment where SUCLA2 then binds to and promotes the formation of stress granules. SUCLA2-mediated stress granules facilitate the protein translation of antioxidant enzymes including catalase, which mitigates oxidative stress and renders cancer cells resistant to anoikis. We provide clinical evidence that SUCLA2 expression correlates with catalase levels as well as metastatic potential in lung and breast cancer patients. These findings not only implicate SUCLA2 as an anticancer target, but also provide insight into a unique, noncanonical function of SUCLA2 that cancer cells co-opt to metastasize.

Indexed as

NeoplasmsSuccinate-CoA LigasesAcyl Coenzyme ACatalaseHumansOxidation-ReductionStress GranulesAcyl Coenzyme ACatalaseSuccinate-CoA Ligasessuccinyl-coenzyme Amitochondrial metabolismredox homeostasisstress granulesuccinyl-CoA ligasetumor metastasis

Identifiers

PMID37253003
PMCPMC10266061
OpenAlexW4378783068

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.